Testing the Dexcom G7 glucose sensor in critically ill surgery and transplant patients
Tests how accurately the Dexcom G7 glucose sensor tracks blood sugar in intensive care patients.
Key facts
- Who runs it
- Institute for Clinical and Experimental Medicine
- Where
- Prague, CzechiaSee the site
- Trial code
- Registry title
- Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy.
- Status
- Recruiting
- People taking part
- 62 people, planned
- Started
- 14 Jan 2026
- Expected to end
- Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Continuous glucose monitor
- Record updated
- 28 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in intensive care after major abdominal surgery or an organ transplant who need blood sugar checks for insulin treatment. It tests how accurate a continuous glucose sensor is.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- People admitted to the intensive care unit who need blood glucose monitoring for insulin therapy.
Main reasons for not taking part
- Taking high-dose ascorbic acid
- Taking acetaminophen above 4g/day
- A physical or mental health condition that stops continuous wear of the sensor, as judged by the physician
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age 18 years or over
- Intensive care unit admission
- Requiring blood glucose monitoring for insulin therapy
Who cannot take part
- Physical or mental health condition precluding continuous wear of the continuous glucose monitor, as judged by the physician
- High-dose ascorbic acid or acetaminophen > 4g/day
Where in Czechia
- Institute of Clinical and Experimental MedicePrague, CzechiaContact: Marek Protus, MDTaking people
About the trial
What the trial wants to find out
Main objective:
Read full original descriptionShow less
The goal is to to determine the accuracy of Dexcom G7 Continuous glucose monitor system in critically ill patients, undergoing major abdominal surgery and solid organ transplantation, in the intensive care unit.
On admission to the intensive care unit or at the end of surgery, two Dexcom G7 sensors are placed in the infraclavicular position.
Sensor number 1 will be blinded and will only be active when paired with the receiver, without the ability to monitor glucose levels.
Sensor number 2 is used for continuous glucose monitoring and can be used to adjust the insulin dose.
Patients will wear the continuous glucose monitoring sensor for a maximum of 10 days, including the time spent in the intensive care unit and the immediate care unit. The study will not interfere with any usual care clinical workflows.
Calibration is only performed on an unblinded sensor. The reference method for calibration is the glucose from the blood glucose meter.
Calibrate on the first day of monitoring: 4 times a day after approximately 6 hours, or if the blood glucose reading from the blood glucose meter is not within the estimated error range of the continuous glucose monitor (difference greater than 1,5mmol/L).
Calibration on days 2 and 3 of monitoring: once in the morning, or when the meter's glucose reading is not within the estimated error range of the continuous glucose monitoring (difference greater than 1,5mmol/L) On subsequent days when the blood glucose meter reading is not within the estimated error range of continuous glucose monitoring (difference greater than 1,5mmol/L).
Hypothesis:
* Ho: No difference in mean absolute relative difference (MARD) between calibrated and non-calibrated sensors. * Ha: Calibrated sensors have lower mean absolute relative difference (δ = 4%, SD = 5%).
Further objectives:
To evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety.
To identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.
The 2 groups in the trial
- Open labeled CGMExisting treatment, for comparison
Additional calibrations performed on CGM device during monitoring period
Treatment: Continuous glucose monitor
- Control labeled CGMSham treatment, for comparison
No additional calibrations performed on CGM device during monitoring period
Treatment: Continuous glucose monitor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Determining the Reliability and Accuracy of the Dexcom G7 Continuous Glucose Monitoring System in the ICU
- Plain-language title
- Testing the Dexcom G7 glucose sensor in critically ill surgery and transplant patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 May 2026